930596-35-3

Basic information

• Product Name: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate
• CAS NO: 930596-35-3
• Molecular Weight: 257.33
• Mol File: 930596-35-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate(930596-35-3)
• EPA Substance Registry System: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate(930596-35-3)

Safety Data

• Hazardous Substances Data: 930596-35-3(Hazardous Substances Data)

Usage

General Description

"(1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate" is a chemical compound with the molecular formula C13H23NO4. It is a derivative of cyclohexanecarboxylic acid, containing a methyl ester group and a tert-butoxycarbonylamino group. (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate is a chiral molecule with two stereocenters, and it exists as a pair of enantiomers. It is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. Its tert-butoxycarbonylamino group protects the amine functionality, enabling selective reactions with other functional groups. (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate is also used as a starting material in the synthesis of various bioactive molecules.

Upstream product

• 222530-34-9 (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclo hexane-1-carboxylic acid 
• 74-88-4 methyl iodide 
• 222530-39-4 (1R,3S)-3-(tert-butoxycarbonylamino)aminocyclohexanecarboxylic acid 
• 202120-10-3 (1S,3R)-3-aminocyclohexylcarboxylic acid methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Pyrimidopyrazole compound, preparation method and application thereof

The invention discloses a pyrimidopyrazole compound, a preparation method and application thereof. The invention provides a pyrimidopyrazole compound shown as formula I or pharmaceutically acceptablesalts thereof. The compound has a relatively good inhibition effect on CDK7.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevent